Skin Cancer

GEP in Melanoma Detection with Darrell S. Rigel, MD, MS
October 22, 2021

In a video onsite at Fall Clinical Dermatology Conference, Darrell S. Rigel, MD, MS, highlights, in his own words, the potential of GEP as an adjunct to biopsy in melanoma detection.

Applying GEP to Melanoma Detection
October 21, 2021

How can GEP be applied to melanoma diagnosis and treatment? Darrel Rigel, MD, MS, answers these questions and dives into the data at Fall Clinical Dermatology Conference 2021.

AI Breakthrough in Melanoma Detection
October 18, 2021

Proscia announces new study data on artificial intelligence’s ability to detect melanoma.

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA
October 14, 2021

The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.

Master the Clues that Mask Malignancy
October 02, 2021

Case-based observations offered clinicians real-world guidance on distinguishing underlying malignancies in the Therapeutic Hotline session at Maui Derm NP+PA Fall 2021.

Coppertone Recalls 12 Lots of Aerosol Sunscreen
October 01, 2021

Coppertone has issued a voluntary recall for 12 lots of its aerosol sunscreen, citing detected levels of the carcinogen benzene.

Nailing the Nail Diagnosis
September 30, 2021

As a part of her Maui Derm NP+PA Fall 2021 presentation, Phoebe Rich, MD, discusses how different diseases manifest in the nails, including multiple patient examples, and whether or not biopsy is needed for diagnosis.

Study: Skin Cancer Detection Apps Fail to Correctly Classify Life-Threatening Cancers
September 30, 2021

The EADV congress today presents new study data showing that skin cancer detection apps fail to correctly categorize rare and aggressive cancers as high-risk.

Pipeline Updates in Melanoma
September 22, 2021

Possible melanoma treatments have had multiple newsworthy events since July 2021.

FDA Accepts Priority Review for Melanoma Treatment
September 22, 2021

Bristol Myers Squibb has announced that the FDA has accepted the Biologics License Application (BLA) for relatlimab and nivolumab, a fixed-dose combination treatment for unresectable or metastatic melanoma.